14 Jan 2025 · 1 min read
One of the first tech-bio deals coming out to JPM this year: Insilico Medicine and MENARINI Group...
One of the first tech-bio deals out of JPM this year sees Insilico Medicine and MENARINI Group deepen their partnership around an AI-discovered asset — not an AI platform — potentially worth up to $550M. I'm curious which business model will emerge as the leader for AI-techbio companies: selling AI platforms and services, or developing your own pipeline.